Medical network - March 17th March 15, drug centralized purchasing platform in yunnan province issued "about the publication of the enterprises to apply for the price, the price of this application is represented by Kant le (Shanghai) pharmaceutical co., LTD. The two varieties of novartis, imatinib mesylate tablets and Nero for capsule three specifications of the products, are mainly used in the treatment of chronic myelogenous leukemia.
But, by studying can be found that the reduction is not big, far less than last year's negotiations two for lung cancer treatment in the drug for the treatment, breeds and ek for more than 50% of the decline.
Note: data from yunnan province drug centralized purchasing platform, for your reference.
▍ why enterprises actively apply for the price?
Consider the national price linkage, the compliance of consideration
With the deepening of the reform policies such as "health charged fees", the strength of the implementation of the "two votes", around the bidding price is more transparent, linkage mechanism. At present, most of the provinces with the lowest price as the price. The two varieties of the novartis initiative to apply for the price of three product is related to the price of other provinces linkage.
Through nearly two years the varieties of bidding price can be found, even by drug companies take the initiative to apply for price cut drug prices, after also not lower than the price in current multiple provinces, even nello for capsule after apply for the price, the price is higher than the current price in the fujian.
Note: according to the provincial drug bidding website, for your reference.
In fact, the author found that, by comparing the past a lot of varieties in yunnan province won the bid prices are relatively high, the enterprise also hope that through the price linkage to control the transregional happening. In addition, no matter from which Angle, drug firms price will be a good thing for patients, so the procurement center province are welcome enterprises take the initiative to reduce the price.
▍ foreign drug companies pressure big, marketing strategy to price in the amount of consideration
By the health insurance fee, foreign branded drugs, such as "patent cliff" comes at present foreign drug companies product price cuts unprecedented pressure. Previously, the health development planning commission led by 16 ministries and national health talks, the first drug firms shortlisted list the treatment of astrazeneca and glaxosmithkline viread prices by 55% and 55% respectively. Foreign and domestic branded drugs sale, no doubt, confirms this point. In addition, domestic beida pharmaceutical ek, is also the first batch of qualified for national health talks list for reduction of 54%. The three varieties were incorporated into the new version of the 2017 get health insurance directory, these varieties in the next few years is rare big probability event.
Novartis, the price of two varieties, imatinib mesylate also added into the medicare catalog in 2017. It will be fine but the varieties in China has a board, jiangsu howson, nolato, group of several hundred strong enterprises such as several generic strong go on sale, and soon the great achievements, zhengda shine, jiangsu, the variety of the terminal sales in the retail price of all in one hundred million yuan of above, according to the annual reports of listed companies, including sales revenue in 2016 of the varieties of zhengda shine hk $155 million. At present, according to the author, novartis, the varieties of the market sales terminal is controlled in 1.5 billion yuan, still occupy the varieties of more than eighty percent market share. Along with the advancement of national generics consistency evaluation, which has the variety approval these enterprises must not miss the opportunity, consistency evaluation at relatively low price advantage in the future form import substitution of the market potential is tremendous. Novartis price at this time, but also to seize the new into the medical insurance directory, domestic complete consistency evaluation of price for quantity, to speed up the pace of monopoly market.
Nero for which currently there is no domestic listed generic drug production sales, but there are already simcere, howson pharmaceutical, chengdu Jian jiang pharmaceutical factory production has entered the application, in the near future into mass production and the sale is a big probability event. In addition, there are a number of manufacturers in the clinical stage. According to the author according to the sample data, novartis Nero for current terminal market sales is less than 500 million yuan, so before the domestic generics production sale in order to cut prices, prices for quantity rapidly expanding market, reduce the impact of the upcoming domestic generics.
▍ is not the first, yunnan drug firms active reduction happens many times
The author through drug centralized purchasing platform in yunnan province website using "apply for price" as keywords retrieval, since in September 2015, has published seven times about the publication of the enterprises to apply for the price, including five in 2016 alone.
From the point of reduction, more than 50% of the DOPPEL FARMACEUTICI S.R.L. 0.25 g, 10 / box of nitrate injunctions, vaginal pills, 50 mg zhejiang pharmaceutical co., LTD. Xinchang pharmaceutical factory, 20 pieces of mig/box column alcohol, liaoning sea cisco pharmaceutical co., LTD. 1 ml: 0.1 mg, maven hydrochloride injection. Drug centralized purchasing platform in yunnan province in 2015-2016 the circumstances of the initiative to apply for the price of the enterprise in the following table:
Note: data from yunnan province drug centralized purchasing platform, for your reference. |
